Treatment outcome in patients with triple negative early stage breast cancers compared with other molecular subtypes |
Kim, Ja Young
(Department of Radiation Oncology, CHA Bundang Medical Center, CHA University)
Chang, Sei-Kyung (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Park, Heily (Department of Radiation Oncology, Presbyterian Hospital) Lee, Bo-Mi (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Shin, Hyun Soo (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) |
1 | Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7. DOI ScienceOn |
2 | Solin LJ, Hwang WT, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triplenegative early-stage invasive breast carcinoma. Clin Breast Cancer 2009;9:96-100. DOI ScienceOn |
3 | Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005;123:16-20. DOI ScienceOn |
4 | Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 2011;22:1554-60. DOI ScienceOn |
5 | Freedman GM, Anderson PR, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breastconserving surgery and radiation. Cancer 2009;115:946-51. DOI ScienceOn |
6 | Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60. DOI ScienceOn |
7 | Kim EK, Noh WC, Han W, Noh DY. Prognostic signifi cance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg 2011;35:1244-53. DOI ScienceOn |
8 | Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48. DOI ScienceOn |
9 | Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-8. DOI ScienceOn |
10 | Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65. DOI |
11 | Noh JM, Choi DH, Huh SJ, et al. Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. J Breast Cancer 2011;14:46-51. DOI ScienceOn |
12 | Yagata H, Kajiura Y, Yamauchi H. Current strategy for triplenegative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011;18:165-73. DOI ScienceOn |
13 | Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52. DOI ScienceOn |
14 | Weigelt B, Mackay A, A'hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010;11:339-49. DOI ScienceOn |
15 | Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. DOI ScienceOn |
16 | Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 2009;115:4917-23. DOI ScienceOn |
17 | Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91. DOI ScienceOn |